|
|
|
Volumn 24, Issue 1 SUPPL. 4, 1997, Pages
|
|
Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa- 2b in melanoma
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
RECOMBINANT ALPHA2B INTERFERON;
ALPHA2B INTERFERON;
ADULT;
ALOPECIA;
ANOREXIA;
BLOOD TOXICITY;
CANCER RECURRENCE;
CANCER SURVIVAL;
CHILL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DEPRESSION;
DIARRHEA;
DOSE RESPONSE;
FATIGUE;
FEMALE;
FEVER;
HEADACHE;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
LYMPH NODE METASTASIS;
MAJOR CLINICAL STUDY;
MALE;
MELANOMA;
MYALGIA;
NAUSEA;
NEUROTOXICITY;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
SUBCUTANEOUS DRUG ADMINISTRATION;
TASTE DISORDER;
VOMITING;
ADJUVANT CHEMOTHERAPY;
ARTICLE;
MIDDLE AGED;
MORTALITY;
RISK ASSESSMENT;
SKIN TUMOR;
CHEMOTHERAPY, ADJUVANT;
FEMALE;
HUMANS;
INTERFERON ALFA-2B;
MALE;
MELANOMA;
MIDDLE AGED;
RANDOMIZED CONTROLLED TRIALS;
RISK ASSESSMENT;
SKIN NEOPLASMS;
|
|
EID: 0031064613
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (40)
|
|
References (12)
|
